Discovery of Orally Active Nonpeptide Vitronectin Receptor Antagonists Based on a 2-Benzazepine Gly-Asp Mimetic-Reference-Cited by-同舟云学术

Discovery of Orally Active Nonpeptide Vitronectin Receptor Antagonists Based on a 2-Benzazepine Gly-Asp Mimetic

Published:1999-12-23 Issue:1 Volume:43 Page:22-26
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Miller William H.¹,Alberts Doreen P.¹,Bhatnagar Pradip K.¹,Bondinell William E.¹,Callahan James F.¹,Calvo Raul R.¹,Cousins Russell D.¹,Erhard Karl F.¹,Heerding Dirk A.¹,Keenan Richard M.¹,Kwon Chet¹,Manley Peter J.¹,Newlander Kenneth A.¹,Ross Stephen T.¹,Samanen James M.¹,Uzinskas Irene N.¹,Venslavsky Joseph W.¹,Yuan Catherine C.-K.¹,Haltiwanger R. Curtis¹,Gowen Maxine¹,Hwang Shing-Mei¹,James Ian E.¹,Lark Michael W.¹,Rieman David J.¹,Stroup George B.¹,Azzarano Leonard M.¹,Salyers Kevin L.¹,Smith Brian R.¹,Ward Keith W.¹,Johanson Kyung O.¹,Huffman William F.¹

Affiliation:

1. Research & Development Division, SmithKline Beecham Pharmaceuticals, 1250 South Collegeville Road, P.O. Box 5089, Collegeville, Pennsylvania 19426-0989, and 709 Swedeland Road, P.O. Box 1539, King of Prussia, Pennsylvania 19406-0939

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/jm990446u

Reference42 articles.

1. ArgGlyAsp (RGD) peptides and the anti-vitronectin receptor antibody 23C6 inhibit dentine resorption and cell spreading by osteoclasts*1

Cited by 120 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Electrophilic Sulfenylation/Cyclization of N‐Aryl and N‐Benzyl Propynamides: Synthesis of Sulfenyl Quinolinones and 3H‐Benzo[c]azepin‐3‐ones;Asian Journal of Organic Chemistry;2023-07-31

2. Graphene-based 3D-Printed nanocomposite bioelectronics for monitoring breast cancer cell adhesion;Biosensors and Bioelectronics;2023-04

3. The challenges and opportunities of αvβ3-based therapeutics in cancer: From bench to clinical trials;Pharmacological Research;2023-03

4. The Chemistry of Creating Chemically Programmed Antibodies (cPAbs): Site-Specific Bioconjugation of Small Molecules;Molecular Pharmaceutics;2023-01-25

5. Loss of ATRX promotes aggressive features of osteosarcoma with increased NF-κB signaling and integrin binding;JCI Insight;2022-09-08